產品描述: | Enasidenib (AG-221) 是一種新型有效的、具有選擇性的IDH2突變酶的可逆抑制劑 |
靶點: |
IDH2(Cell-free assay):12 nM;Dehydrogenase;IsocitrateDehydrogenase(IDH) |
體外研究: |
AG-221降低>90%的2-HG水平,在體外逆轉組蛋白和DNA的過度甲基化;在白血病細胞中誘導細胞分化 |
體內研究: |
AG-221能夠有效降低移植小鼠骨髓、血漿和尿液中2-HG水平。AG-221的處理還可誘導劑量依賴式的、統計上顯著的生存益處。AG-221處理、細胞分化后,人類特異的CD45+胚細胞爆發式增殖。 AG-221還可恢復由突變體IDH2表達抑制的MEP分化、逆轉突變體IDH2在突變干/祖細胞中對DNA甲基化效應。臨床實驗中,IDH2抑制劑和其他靶向AML的療法相結合,對于提高治療效果是十分必要的 |
細胞實驗: |
Cell lines: OE19 cells Concentrations: 5 μM Incubation Time: 24 h Method: Cells were treated with different concentrations of Enasidenib. |
動物實驗: |
Animal Models: 攜帶IDH2突變的白血病小鼠模型 Dosages: 10mg/kg or 100mg/kg bid Administration: -- |
參考文獻: |
1. Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood. 2014, 124:437. 2. Kate Ellwood-Yen, et al. Abstract 3116: AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model. AACR. 2014, 74(19 Sup.):3116. 3. Ogden S, et al. Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition. Oncogene. 2022 Oct;41(43):4808-4822. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.112 ml |
10.562 ml |
21.125 ml |
5 mM |
0.422 ml |
2.112 ml |
4.225 ml |
10 mM |
0.211 ml |
1.056 ml |
2.112 ml |
50 mM |
0.042 ml |
0.211 ml |
0.422 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |